A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults

Cephalalgia

Volumn 24, Issue 4, 2004, Pages 288-292

  Baldwin, J R ^a,b   Fleishaker, J C ^a   Azie, N E ^a   Carel, B J ^a  

^a Pharmacia ^*  (United States)

^b Clinical Pharmacology   (United States)

Author keywords

5 HT1B 1D agonist; Adolescents; Almotriptan; Migraine; Pharmacokinetics

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST;

ADOLESCENT; ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INCIDENCE; KIDNEY CLEARANCE; MALE; MIGRAINE; NORMAL HUMAN; SCHOOL CHILD; SIDE EFFECT; URINARY EXCRETION; XEROSTOMIA;

ADOLESCENT; ADULT; AGE FACTORS; AREA UNDER CURVE; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HALF-LIFE; HUMANS; INDOLES; MALE; MIGRAINE DISORDERS; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 1842507516     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00673.x     Document Type: Article

References (14)

1. Bille B. Migraine in school children. Acta Paediatr 1962; 51 (Suppl. 136):1-147.
2. Humphrey PPA, Feniuk W, Perren MJ, Beresford IJM, Skingle M, Whalley ET. Serotonin and migraine. Ann NY Acad Sci 1990; 600:587-98.
3. Bou J, Domènech T, Gras J, Beleta J, Llenas J, Fernández AG, Palacios JM. Pharmacological profile of almotripan, a novel antimigraine agent. Cephalalgia 1997; 17:421-2 [Abstract].
4. Robert M, Warrington SJ, Zayas SJ, Cabarrocas X, Fernandez JF, Ferrer P. Electrocardiographic effects and pharmacokinetics of oral almotriptan in healthy subjects. Cephalalgia 1998; 18:406 [Abstract].
5. Cabarrocas X, Salvá M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug. Cephalalgia 1997; 17:421-2 [Abstract].
6. Salvà M, Costa J, Palacios JM, Martinez-Tobed A. Metabolism of the novel anti-migraine compound almotriptan (LAS 31416) in humans [Abstract]. In: Proceedings of the Sixth European Meeting of the International Society for the Study of Xenobiotics Meeting. June 30 to July 3, 1997, Gothenburg, Sweden. Gothenburg: The Society, 1997.
7. Fleishaker JC, Ryan KK, Jansat JM, Carel BJ, Bell DJ, Burke MT, Azie ME. Effect of MAO-A inhibition on the pharmacokinetics of almotripan, an antimigraine agent in humans. Br J Clin Pharmacol 2001; 51:437-41.
8. Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther 2000; 67:498-503.
9. Unites States National Center for Health Statistics. Clinical growth charts, 2000; http://www.cdc.gov/nchs/about/ major/nhanes/growthcharts/ clinical_charts.htm
10. SAS Institute, Inc. SAS/STAT user's guide, Version 8.2. Cary, NC: SAS Institute, Inc., 1999.
11. Jhee SS, Shiovitz T, Crawfor AW, Cutler N. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents. Clin Pharmacokinetics 2001; 40:189-205.
12. Cabarrocas X, Jansat JM, Ferrer P, Luria X. Pharmacokinetics of oral almotriptan during and outside a migraine attack. Cephalalgia 2000; 20:417-8 [Meeting].
13. Evans WE, Relling MV, de Graaf S, Rodman JH, Pieper JA, Christensen ML, Crom WR. Hepatic drug clearance in children: studies with indocyanine green as a model substrate. J Pharmacol Exp Ther 1989; 78:452-6.
14. Dixon R, Engleman K, Kemp J, Ruckle J. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults. J Child Adolescent Psychopharmacol 1999; 9:35-42.